Listing 13.17 Small Intestine Cancer in 2026
Small bowel cancer flies under the radar. Only about 12,510 new cases will be diagnosed in the US in 2026, per American Cancer Society projections, with roughly 2,110 deaths. Compare that to 154,270 new colorectal cases. That's why most people, including some primary care doctors, don't recognize it until it's advanced. Vague abdominal pain, anemia from occult bleeding, or bowel obstruction are common ways it shows up.
SSA groups all small intestine cancers into Listing 13.17: adenocarcinoma, neuroendocrine (carcinoid), gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma. Different biologies, different treatments, one listing. If your case fits the listing rule, you don't need to argue functional limitations. The listing is enough.
Get a free case check in 60 seconds. Compassionate Allowance may apply.
See If You Qualify
The Listing 13.17 rule
Here is the exact Blue Book language for Listing 13.17:
Small intestine cancer that is inoperable, unresectable, recurrent, or has metastasized beyond the regional lymph nodes.
One sentence. Four qualifying conditions. Meet any one and the medical piece is done. No RFC analysis. No functional capacity workup. That's why this listing, when the documentation lines up, moves fast.
The five cancer types covered
Adenocarcinoma
The most common small bowel cancer overall. About 40-50% of cases. Most cases arise in the duodenum, followed by jejunum, then ileum. Risk factors include Crohn's disease, celiac disease, familial adenomatous polyposis, Lynch syndrome, and Peutz-Jeghers syndrome. Standard treatment for resectable disease is surgical resection with regional lymphadenectomy. Adjuvant FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) is often used for stage III disease. Metastatic disease usually gets treated like metastatic colorectal cancer: FOLFOX or FOLFIRI plus bevacizumab or an EGFR inhibitor if RAS wild-type, though small bowel adenocarcinoma is less well-studied than colorectal.
Five-year survival by stage per SEER 2026 data: Stage I about 74%, Stage II about 51%, Stage III about 34%, Stage IV about 12%.
Neuroendocrine tumors (carcinoid)
Small bowel is one of the most common sites for neuroendocrine tumors. About 30% of small bowel cancers overall. These grow slowly and often present with carcinoid syndrome (flushing, diarrhea, right-sided heart valve disease) when liver metastases produce enough serotonin to bypass hepatic clearance. Standard treatment includes surgical resection when feasible, plus long-acting somatostatin analogs (lanreotide, octreotide LAR) for symptom control and tumor stabilization. Lutathera (lutetium Lu-177 dotatate) is peptide receptor radionuclide therapy approved for progressive somatostatin-receptor-positive tumors. Everolimus and sunitinib are used in select cases.
Five-year survival for small bowel NET: Localized about 88%, regional about 78%, distant about 68%. Better than adenocarcinoma survival, but not benign. Advanced disease with liver metastases still meets Listing 13.17 under the metastatic prong.
Gastrointestinal Stromal Tumors (GIST)
About 15% of small bowel cancers. Mesenchymal origin, KIT or PDGFRA mutation driven. The revolution in GIST treatment came from imatinib (Gleevec), which turned metastatic GIST from a rapidly fatal disease into one where median survival now runs 5-10 years. Second-line and later options include sunitinib, regorafenib, ripretinib, and avapritinib for PDGFRA D842V mutants.
GIST survival depends heavily on tumor size, mitotic rate, and mutation status. Small bowel GIST tends to behave more aggressively than gastric GIST. Metastatic GIST meets Listing 13.17. So does inoperable GIST, which happens when the primary tumor invades vital structures.
Lymphoma of the small intestine
About 10-15% of small bowel cancers. Most are B-cell lymphomas: diffuse large B-cell lymphoma (DLBCL), MALT lymphoma, mantle cell lymphoma, and follicular lymphoma. T-cell lymphomas are less common but include enteropathy-associated T-cell lymphoma (EATL) in celiac disease patients. Treatment depends on subtype: R-CHOP for DLBCL, rituximab-based regimens for indolent lymphomas, CHOEP or brentuximab-based regimens for T-cell lymphomas.
Note that Listing 13.05 covers lymphoma generally. Small bowel lymphoma can theoretically qualify under either 13.05 or 13.17. DDS usually uses whichever listing is easier to satisfy. Aggressive lymphomas typically meet 13.05 based on the treatment protocol requirements.
Sarcoma of the small intestine
Rare, less than 5% of small bowel cancers. Leiomyosarcoma is the classic example. Treatment is surgical resection with adjuvant chemo (doxorubicin-based) for high-grade cases. Metastatic small bowel leiomyosarcoma is treated with doxorubicin, gemcitabine plus docetaxel, or trabectedin.
The four qualifying conditions in detail
Inoperable
Surgery can't be performed safely due to tumor location, patient comorbidities, or extent of disease. For small bowel cancer, this is less common than in bone or pancreatic cancer because most small bowel tumors are technically resectable. When inoperability applies, it's usually due to extensive local invasion (superior mesenteric artery involvement, extensive bowel involvement that would require short-bowel-syndrome-producing resection) or patient factors (advanced age, severe cardiopulmonary disease, refusal of surgery after informed consent).
Unresectable
Complete removal with negative margins isn't feasible. For duodenal tumors, this can mean encasement of the superior mesenteric vessels, portal vein, or common bile duct. For jejunal or ileal tumors, this is rare unless there's diffuse involvement or peritoneal spread.
Recurrent
Cancer returns after primary treatment. Any recurrence pattern qualifies (local, regional, or distant). For small bowel cancer, recurrence often shows up as peritoneal disease, liver metastases, or lymph node disease. Even a small volume recurrence discovered on surveillance imaging counts.
Metastasized beyond regional lymph nodes
Distant metastases. The most common sites for small bowel cancer:
- Adenocarcinoma: Liver, peritoneum, lung, bone.
- NET (carcinoid): Liver (very common), bone, lung, distant lymph nodes.
- GIST: Liver and peritoneum. Rare lung and bone.
- Lymphoma: Bone marrow, spleen, distant nodes, CNS.
- Sarcoma: Lung, liver, bone.
Compassionate Allowance and small bowel cancer
Small bowel cancers are not on SSA's Compassionate Allowance list as a specific entry. But the following related conditions are:
- Small cell carcinoma of large intestine (Compassionate Allowance).
- Small intestine cancer with distant metastases can sometimes get flagged under related CAL criteria.
- Cancer of unknown primary (CUP) if pathology is inconclusive (see the Listing 13.27 CUP article).
Even without an official CAL flag, Stage IV small bowel cancer with distant metastases moves quickly at DDS when the pathology and imaging documentation are clean.
Evidence checklist for a strong 13.17 application
- Pathology report naming the tumor type (adenocarcinoma, NET, GIST, lymphoma, sarcoma), grade, and any molecular findings (KIT/PDGFRA mutation for GIST, Ki-67 for NET, immunohistochemistry for lymphoma).
- Imaging including CT abdomen/pelvis, chest CT, MRI enterography if performed, and PET-CT for NET or aggressive tumors. For GIST and NET, DOTATATE PET is often part of the workup.
- Endoscopy reports (upper endoscopy, capsule endoscopy, single or double balloon enteroscopy).
- Surgical operative report if surgery was performed, documenting the resection and any findings of unresectability or metastases.
- Oncology treatment plan naming the regimen (FOLFOX, R-CHOP, imatinib, lanreotide, Lutathera, etc.), cycles completed, and response.
- Any tumor board consensus notes for cases where a treatment strategy was debated.
Treatment realities that affect the case
FOLFOX for small bowel adenocarcinoma
Standard adjuvant and metastatic regimen. Oxaliplatin causes cumulative peripheral neuropathy that can persist for years after treatment. Fatigue, cold sensitivity, and hand-foot syndrome are common. In cases where the listing prong isn't clearly met, these side effects can support a Medical-Vocational finding.
Imatinib for GIST
Imatinib turned metastatic GIST into a chronic disease. Patients often stay on it for years. Chronic side effects include periorbital edema, fatigue, muscle cramps, and occasional cardiac toxicity. Even though patients on imatinib may look "stable," the metastatic status alone meets Listing 13.17. Post-approval, CDRs on GIST cases often extend to 5 or 7 years given the disease trajectory.
Lanreotide and Lutathera for neuroendocrine tumors
Lanreotide is a long-acting somatostatin analog given monthly by deep subcutaneous injection. It slows tumor growth and controls symptoms in carcinoid syndrome. Lutathera is peptide receptor radionuclide therapy: four IV infusions of Lutetium-177 dotatate over 8 months. Approved for progressive somatostatin-receptor-positive gastroenteropancreatic NETs. Side effects include nausea, fatigue, myelosuppression, and rare secondary malignancies.
Metastatic NETs on Lutathera clearly meet Listing 13.17 metastatic prong. Even localized NETs may qualify if unresectable or recurrent.
R-CHOP for small bowel lymphoma
Standard for DLBCL. Six cycles over 18 weeks. Rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Common side effects: myelosuppression, infection risk, cardiotoxicity from doxorubicin, neuropathy from vincristine.
Timeline from filing to payment
| Scenario | Typical Decision Time | Notes |
|---|---|---|
| Metastatic small bowel adenocarcinoma | 30-60 days | Clear listing match, often expedited |
| Metastatic small bowel NET on Lutathera | 30-90 days | Clear listing match if metastatic; RFC path if localized/stable |
| Metastatic GIST on imatinib | 30-90 days | Meets listing but CDR is longer given disease chronicity |
| Recurrent small bowel cancer of any type | 45-90 days | Recurrence documentation is essential |
| Resected Stage I-II small bowel cancer no recurrence | 3-6 months, often denied at initial | RFC path with post-op complications and neuropathy |
Common denial reasons and fixes
1. Regional node involvement treated as metastasis
Fix: Mesenteric and celiac nodes are regional for small bowel cancer. If your only "metastasis" is regional nodes, the listing metastatic prong isn't met. Look to inoperable, unresectable, or recurrent instead.
2. NET labeled "well-differentiated" without discussion of extent
Fix: Well-differentiated NET can still meet the listing if metastatic or unresectable. Get your oncologist to specify tumor location, Ki-67 index, and extent of disease including liver mets or nodal disease.
3. GIST responding to imatinib called "stable" or "in remission"
Fix: Response to imatinib doesn't negate metastatic status for listing purposes. Once metastatic, the listing is met at the time of decision. Your oncologist should confirm metastatic disease is present, even if controlled.
4. Lymphoma routed to Listing 13.05 but wrong subtype criteria applied
Fix: Sometimes DDS applies the wrong hematologic listing subsection. If your DLBCL isn't meeting 13.05's specific criteria, argue Listing 13.17 as the small bowel primary.
5. Path report inconclusive about tumor type
Fix: Push for additional immunohistochemistry, molecular testing, or a second-opinion pathology review at a high-volume center. NET vs adenocarcinoma vs GIST changes both treatment and listing analysis.
State-specific processing times
Applicants in California, Texas, Florida, and New York see initial DDS decisions in 90-120 days on average. Expedited or Compassionate Allowance-adjacent cases can move in 30 days or less. Southern states including Alabama, Mississippi, and West Virginia tend to have longer wait times but often higher approval rates at initial for clear-listing cases.
Related listings and cross-references
- Listing 13.05 covers lymphoma generally. Small bowel lymphoma can qualify under either 13.05 or 13.17.
- Listing 13.18 covers large intestine cancer (colon and rectum).
- Listing 13.20 covers pancreatic cancer.
- Listing 13.27 covers primary site unknown (cancer of unknown primary) if pathology is inconclusive.
See also: Why was my disability denied in 2026 and Denial Notice Anatomy 2026.
Frequently Asked Questions
Is small bowel adenocarcinoma covered by the same listing as colon cancer?
No. Colon and rectal cancers fall under Listing 13.18. Small intestine cancers, including duodenal, jejunal, and ileal adenocarcinomas, fall under Listing 13.17.
Do carcinoid tumors of the small bowel automatically qualify?
Not automatically. They qualify if inoperable, unresectable, recurrent, or metastasized beyond regional lymph nodes. Localized resected NET without recurrence usually does not meet the listing, though carcinoid syndrome symptoms can support a Medical-Vocational finding.
What if I have GIST that has been controlled on imatinib for years?
Metastatic GIST meets Listing 13.17 regardless of imatinib response. Your CDR after approval may be longer given GIST's chronic-disease trajectory on TKI therapy, and SSA may reassess your case at 5 or 7 years post-approval.
Does Lutathera count as a treatment that supports my disability case?
Yes, indirectly. Lutathera is prescribed for progressive somatostatin-receptor-positive NETs. Being on Lutathera signals metastatic or progressive disease, which supports the listing metastatic prong.
What if my small bowel cancer was found incidentally during surgery for something else?
Incidental finding doesn't change the listing analysis. What matters is the pathology, staging, and treatment course. If the cancer meets one of the four qualifying conditions (inoperable, unresectable, recurrent, metastatic beyond regional nodes), the listing is met.
Can I qualify with Peutz-Jeghers syndrome or Lynch syndrome plus small bowel cancer?
The underlying genetic syndrome doesn't add to the listing analysis directly. What matters is whether your current cancer meets the listing. That said, hereditary cancer syndromes often mean multiple primary tumors over time, which can strengthen the durational analysis and cumulative functional impact.
How long is the 5-month waiting period for SSDI with small bowel cancer?
Standard SSDI 5-month waiting period from established onset date applies. In many small bowel cancer cases, the onset date is set months before the application filing date (based on when symptoms began and diagnosis was made), so the waiting period may already be satisfied by the time you get a decision.